Please provide your email address to receive an email when new articles are posted on . Patients with asthma who switched from a metered-dose inhaler to a dry-powder inhaler cut their inhaler carbon ...

The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

Switching from a metered-dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

The divided solid materials have a significant share in the products produced or employed in the pharmaceutical industries (such as active pharmaceutical ingredient (API), excipients, additives, and ...

multiple inhalers on a white background Researchers explored the association between dry powder inhaler technique errors and exacerbations and health status in patients with COPD. Severe COPD ...

Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...

Please provide your email address to receive an email when new articles are posted on . The dry powder formulation of treprostinil studied in BREEZE is in development with a reusable breath-powered ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive ...

The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...

Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...